Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study.

By G. Bleumink, Anneke M. Knetsch, M. Sturkenboom, S. Straus, Albert Hofman, J. Deckers, J. Witteman, B. Stricker. European Heart Journal, 2004

1,200 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine

View Paper: https://www.semanticscholar.org/paper/746fd863380c0b673e5d6a5d0949257fb81a7d30

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. G. Lopaschuk
2. Véronique L. Roger
3. K. Weeks
4. Bianca C. Bernardo
5. J. McMullen

Citations in the corpus

• 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure (2016, neutral): “The lifetime risk of HF at age 55 years is 33% for men and 28% for women.(16) The proportion of patients with HFpEF ranges from 22 to 73%, depending on the definition applied, the clinical setting (primary care, hospital clinic, hospital admission), age and sex of the studied population, previous my”
• Myocardial substrate metabolism in the normal and failing heart. (2005, background): “It is important to consider that the incidence of HF is directly related to age (33) and that the progression from adulthood to senescence affects cardiac contractile properties and LV chamber size (241, 242, 422), myocardial flow reserve (471) and cardiac mitochondria function (104, 147, 253, 276),”
• Epidemiology of Heart Failure (2013, result): “In the Rotterdam Heart Study, the lifetime risk of HF at the age of 55 years was 33% for men and 29% for women.(77) These numbers are commensurate with the data from the United States.”
• The Rotterdam Study: 2010 objectives and design update (2007, background): “and lifetime risk of heart failure and atrial fibrillation in an elderly population [33, 34].”
• Ablation Versus Amiodarone for Treatment of Persistent Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted Device: Results From the AATAC Multicenter Randomized Trial (2016, background): “unplanned hospitalization and significantly impacts healthcare costs.(37) Therefore, the reduction of unplanned hospi-”
• Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies. (2010, background): “Currently there is no cure for heart failure, and long termsurvival following heart failure remains poor, with one third of patients dying within a year of diagnosis (Zannad et al., 1999; Cowie et al., 2000; Bleumink et al., 2004; McMurray & Pfeffer, 2005).”